Quick Summary
- ARK Invest acquired approximately $19.4M in CoreWeave shares during a 19% stock decline triggered by mixed Q4 results
- The fund’s most substantial transaction involved purchasing $23.2M worth of Kratos Defense & Security Solutions stock
- Teradyne faced continued selling pressure from ARK, with $12.9M in shares exiting the portfolio
- ARK reduced its Rocket Lab holdings following an earnings report that exceeded forecasts but resulted in a ~5% share price decline
- Additional transactions included Roku sales and an investment in biotech company Generate Biomedicines
Cathie Wood’s ARK Invest executed multiple portfolio adjustments on Friday, February 27. The trading activity encompassed fresh acquisitions and position reductions spanning technology, defense, and biotechnology sectors.
Kratos Defense & Security Solutions received ARK’s largest capital allocation for the day. The fund acquired 252,169 shares valued at $23.2 million. Kratos specializes in unmanned aerial vehicles and autonomous defense technologies, aligning with ARK’s investment philosophy around robotics and automation.
CoreWeave represented the second-largest acquisition, with ARK purchasing 198,980 shares totaling approximately $19.4 million. These shares were distributed between the ARKK and ARKW ETFs.
CoreWeave, Inc. Class A Common Stock, CRWV
ARK’s CoreWeave purchase occurred during a session where shares tumbled 19%. The decline followed fourth-quarter financial results that demonstrated robust revenue growth alongside expanding losses and capital expenditures exceeding market forecasts.
The timing of ARK’s acquisition during the price decline indicates the firm interprets the selloff as a temporary market overreaction. CoreWeave operates in AI computing infrastructure, a sector experiencing accelerating demand.
Analyst consensus for CoreWeave stands at Moderate Buy across Wall Street. The mean price target of $114.18 suggests potential appreciation of approximately 43.5% from current trading levels, derived from eleven Buy recommendations and eight Hold ratings.
Teradyne and Rocket Lab Face Portfolio Cuts
ARK divested 38,773 Teradyne shares valued at $12.9 million across several ETFs. Teradyne manufactures semiconductor testing equipment and industrial automation solutions. This transaction continues ARK’s recent pattern of scaling back its Teradyne exposure.
The fund also liquidated 46,921 shares of Rocket Lab valued at approximately $3.4 million. Rocket Lab had recently announced quarterly performance exceeding both earnings and revenue projections, yet shares dropped roughly 5% on Friday.
Rocket Lab disclosed robust launch operations and an expanding order pipeline. The company’s timeline for the inaugural Neutron rocket launch shifted to late 2026, potentially contributing to investor caution.
Additional Portfolio Adjustments in Biotech and Technology
ARK divested 46,389 shares of Roku worth $4.3 million from the ARKK ETF. The rationale behind this divestment remains undisclosed.
Within biotechnology, ARK purchased 459,525 shares of Generate Biomedicines valued at $7.4 million through the ARKG ETF. Simultaneously, the fund sold 39,423 shares of Ionis Pharmaceuticals for $3.2 million.
Deere & Co saw ARK reduce its position by 10,590 shares worth $6.6 million, while Guardant Health experienced a trim of 27,334 shares valued at $2.7 million.
Minor adjustments included decreasing PagerDuty holdings by 205,211 shares for $1.5 million and acquiring 14,097 shares of Brera Holdings for approximately $15,600.
The combined CoreWeave and Kratos acquisitions represented ARK’s two most significant individual transactions on February 27, accounting for more than $42 million in total capital deployment.
